RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nabriva Therapeutics Stock

Nabriva Therapeutics Employees 2024

Nabriva Therapeutics Employees

162

Ticker

NBRV

ISIN

IE00BL53QQ85

WKN

A2QKWR

In 2024, Nabriva Therapeutics employed 162 people, a 0% change from the 162 number of employees in the previous year.

Nabriva Therapeutics Aktienanalyse

What does Nabriva Therapeutics do?

Nabriva Therapeutics PLC is a biopharmaceutical company based in Dublin that focuses on the research, development, and marketing of antibiotics for medical needs. The company was founded in 2006 and has since become the leading provider of antibiotics for infectious diseases in Europe and the USA. Nabriva Therapeutics' business model aims to improve the production of antibiotics for acute infections and develop innovative drugs for use in clinical practice and emergency settings. It specializes in serious and life-threatening infections such as pneumonia, bacterial skin and soft tissue infections, and bacterial infections of the urinary tract. The company is divided into two business segments: antibody therapeutics and antibiotics. Antibody therapeutics stimulate the body's immune system to better fight pathogens, while antibiotics directly combat and inhibit the growth of bacteria. Nabriva Therapeutics' flagship product is the antibiotic Xenleta (Levofloxacin) for the treatment of pneumonia. Xenleta is a bactericidal antibiotic that is effective against a variety of difficult-to-treat pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus with reduced susceptibility to Vancomycin (VSSA), acting directly on bacteria. It has been reviewed and approved by the FDA. Nabriva Therapeutics has also advanced the development of Contepo (Fosfomycin) in the field of antibiotics. Contepo is a broad-spectrum antibiotic that is effective against gram-positive and gram-negative bacteria and is intended for the treatment of infectious diseases of the urinary tract. Nabriva Therapeutics has submitted a support application to the FDA for the approval of Contepo for the therapy of complicated urinary tract infections. In August 2020, Nabriva Therapeutics announced the completion of an agreement with Taiho Pharmaceutical Co., Ltd. to market Xenleta in Brazil. The company has also entered into a collaboration with Merck and Co.'s biopharmaceutical organization to investigate the potential of Xenleta for treating patients with diseases such as bacterial skin and soft tissue infections and lung infections. Overall, Nabriva Therapeutics has played an important role in the development of antibiotics for infectious diseases and the fight against antibiotic resistance. With its innovative products and collaboration with other biopharmaceutical organizations, Nabriva Therapeutics has improved its position in the industry and strengthened its leadership in the field of antibiotic therapy. Nabriva Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Nabriva Therapeutics's Employee Base

Nabriva Therapeutics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Nabriva Therapeutics's operational capacity and future potential.

Year-to-Year Comparison

Assessing Nabriva Therapeutics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Nabriva Therapeutics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Nabriva Therapeutics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Nabriva Therapeutics stock

How many employees does Nabriva Therapeutics have this year?

Nabriva Therapeutics has 162 undefined employees this year.

How many employees did Nabriva Therapeutics have compared to the previous year?

Compared to the previous year, Nabriva Therapeutics had 0% more employees.

What impact did the number of employees have on the company Nabriva Therapeutics?

The number of employees has a direct impact on the efficiency and productivity of Nabriva Therapeutics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Nabriva Therapeutics?

The number of employees can also have an impact on investors of Nabriva Therapeutics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Nabriva Therapeutics affect the company?

An increase in equity of Nabriva Therapeutics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Nabriva Therapeutics's equity affect the company?

A reduction in equity of Nabriva Therapeutics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Nabriva Therapeutics?

Some factors that can influence the equity of Nabriva Therapeutics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Nabriva Therapeutics so important for investors?

The equity of Nabriva Therapeutics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Nabriva Therapeutics influence the company?

The number of employees at Nabriva Therapeutics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Nabriva Therapeutics evolved in recent years?

In recent years, the number of employees at Nabriva Therapeutics has changed by 0.

How many employees does Nabriva Therapeutics currently have?

Nabriva Therapeutics currently has 162 undefined employees.

Why is the number of employees important for investors of Nabriva Therapeutics?

The number of employees is important for investors of Nabriva Therapeutics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Nabriva Therapeutics take to change the number of employees?

To change the number of employees, Nabriva Therapeutics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Nabriva Therapeutics pay?

Over the past 12 months, Nabriva Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nabriva Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nabriva Therapeutics?

The current dividend yield of Nabriva Therapeutics is .

When does Nabriva Therapeutics pay dividends?

Nabriva Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nabriva Therapeutics?

Nabriva Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nabriva Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nabriva Therapeutics located?

Nabriva Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nabriva Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nabriva Therapeutics from 11/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/30/2024.

When did Nabriva Therapeutics pay the last dividend?

The last dividend was paid out on 11/30/2024.

What was the dividend of Nabriva Therapeutics in the year 2023?

In the year 2023, Nabriva Therapeutics distributed 0 USD as dividends.

In which currency does Nabriva Therapeutics pay out the dividend?

The dividends of Nabriva Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nabriva Therapeutics

Our stock analysis for Nabriva Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nabriva Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.